Near East University Becomes a Co-Owner of a Newly Registered Patent on an Anthraquinone Derivative
Near East University has become one of the co-owners of a newly registered patent titled “Anthraquinone Derivative, Synthesis and Uses”, granted by the Turkish Patent and Trademark Office under the patent number TR 2019 22464 B. The patent was jointly registered by Istanbul University-Cerrahpaşa, Istanbul Arel University, Near East University and Erciyes University, reflecting the importance of multi-institutional collaboration in transforming scientific research into intellectual property.
The invention focuses on a newly developed thioanthraquinone compound, its synthesis method and its potential uses. Anthraquinone derivatives are known for their broad range of chemical, biological and electrochemical properties, making them an important class of compounds for research in different scientific fields. In this context, the patented compound represents a research output with potential relevance not only for pharmaceutical sciences, but also for antioxidant materials, medical imaging systems, and energy conversion and storage technologies.
According to the patent documentation, the invention includes the synthesis of a novel anthraquinone derivative with the chemical formula 1-(1-Hydroxyhexan-3-ylthio)anthracene-9,10-dione. The patented method describes the synthesis process of this compound and outlines possible fields of application. These include its potential use in pharmaceutical compositions, particularly in cancer-related research, as well as in antioxidant-based materials, food packaging systems, textile products, medical imaging systems, and next-generation energy storage systems such as lithium-ion batteries, organic batteries, supercapacitors and redox flow batteries.
One of the notable scientific aspects of the invention is its potential relevance to cancer research. The patent text indicates that the compound may be considered for use in cancer treatment research, with particular reference to breast cancer and triple-negative breast cancer models. Triple-negative breast cancer remains an important research focus due to its limited response to hormone-based therapies and its tendency to show resistance to conventional chemotherapeutic approaches. Within this framework, the patented compound contributes to ongoing efforts to explore new molecular structures with possible anticancer activity.
Beyond its biomedical potential, the invention also points to the interdisciplinary nature of contemporary innovation. The same compound class may offer value in different fields, ranging from pharmaceutical formulation to electrochemical applications. This broad applicability highlights how a single research output can connect chemistry, health sciences, materials science and energy technologies within a shared innovation framework.
For Near East University, the registration of this patent represents an important contribution to its growing research and innovation ecosystem. It demonstrates the university’s capacity to participate in collaborative scientific production that extends beyond academic publication and moves toward protected intellectual property. By supporting research that has the potential to generate practical, evidence-based and technology-oriented outcomes, Near East University continues to strengthen its role in knowledge production, interdisciplinary innovation and societal impact.